COLUMBIA, Md.--(BUSINESS WIRE)-- Ambu A/S., the world leader in single-use endoscopes, announced today that it has been granted a national single-use endoscopy contract in the category of Single-Use Endoscopes with a major U.S. Group Purchasing Organization (GPO). This contract gives Ambu a sole position in both single-use bronchoscopes and single-use rhinolaryngoscopes for the duration of the contract.

The single-use endoscopy category is new for the GPO and will be effective through November 2023 and enables Ambu to more effectively serve 160 acute care hospitals in the United States and over 2,600 total sites across 20+ states. This agreement can further accelerate Ambu’s share of the single-use endoscope market by giving those accounts pre-negotiated pricing and terms for Ambu’s bronchoscopy and rhinolaryngoscopy products.

“We’re seeing a trend that GPOs now create dedicated single-use endoscopy categories which means that hospitals and health care providers get easier access to advanced single-use devices. With our portfolio in innovative single-use endoscopy, we are the ideal partner to help medical professionals prevent device-related infections and improve healthcare economics,” said Juan Jose Gonzalez, CEO of Ambu A/S.

20 new endoscopy devices over the next three years

Ambu launched the world’s first single-use flexible bronchoscope, the Ambu® aScopeTM in 2009. In 2020, more than 1 million Ambu single-use endoscopes will be used in more than 6,000 hospitals making Ambu the world’s largest supplier of single-use endoscopes.

Within bronchoscopy, 96% of the top 500 hospitals in the U.S. are using Ambu’s sterile, single-use bronchoscopes in the OR and ICU setting. In the last 12 months, Ambu has increased its single-use market share in the U.S., as the market continues to transition to single-use bronchoscopy to avoid costly and unnecessary expenses associated with work-flow management and patient cross-contamination.

In 2020, Ambu launched three new products within our Visualization business. We received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in April 2020 for our single-use cystoscope, and in July 2020 the FDA cleared our single-use duodenoscope. Further, in May 2020 we introduced our new full-HD monitor technology platform to be used across the range of Ambu’s sterile, single-use endoscopes. By 2023, Ambu expects to introduce another 20 new devices across all major areas of endoscopy, including GI, the largest endoscopy market globally.

About Ambu

Ambu has been bringing the solutions of the future to life since 1937. Today, millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anesthesia, and patient monitoring & diagnostics solutions. The manifestations of our efforts have ranged from early innovations like the Ambu® BagTM resuscitator and the Ambu® BlueSensorTM electrodes to our newest landmark solutions like the Ambu® aScopeTM – the world’s first single-use flexible endoscope. Moreover, we continuously look to the future with a commitment to deliver innovative quality products that have a positive impact on the work of doctors, nurses and paramedics. Headquartered near Copenhagen in Denmark, Ambu employs approximately 4,000 people in Europe, North America and the Asia Pacific. For more information, please visit ambu.com or ambuUSA.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201214005819/en/